LIT-001

LIT-001 improves social interaction in a mouse model of autism.It is the first nonpeptide oxytocin receptor agonist with EC50 of 55 nM and Ki of 226 nM.In the in vitro signal transduction experiment, LITL-001 is an unbiased OT-R agonist, acting on the two main signal transduction pathways of this receptor, with slight antagonistic effect on V1a and agonist effect on V1b receptor, only observed at high concentration.LIT-001 (10-20 mg/kg; i.p.) alleviates core symptoms in the context of autism spectrum disorders (ASD) .